Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PortugalBack to Portugal

Clinical trials in Guimaraes – page 17

686 clinical trials in Guimaraes, Portugal across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Guimaraes at a glance
686
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

686 trials in Guimaraes

Open in trial search

Triple negative breast cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing Nemtabrutinib, Ibrutinib, and Acalabrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma refractory

Recruiting

Study Comparing Mezigdomide, Bortezomib, and Dexamethasone with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Celgene Corp.

Lennox-Gastaut syndrome

Recruiting

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Carisbamate
  • Sponsor:Sk Life Science Inc.

Metabolic disorder

Recruiting

Long-Term Safety Study of GLM101 for Patients with PMM2-CDG

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Glycomine Inc.

Crohn's disease

Recruiting

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Alimentiv Inc.

Colitis ulcerative+2

Recruiting

Study on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on the Effectiveness and Safety of Riliprubart Compared to Intravenous Immunoglobulin in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Riliprubart
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm malignant

Recruiting

Study on the Long-Term Safety of Futibatinib and Fulvestrant for Patients with Malignant Solid Tumors

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Taiho Oncology Inc.

Small cell lung cancer+1

Recruiting

Study on BI 764532 for Patients with Relapsed or Refractory Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Sponsor:Boehringer Ingelheim International GmbH

Generalised tonic-clonic seizure+1

Recruiting

Study on the Long-term Safety and Tolerability of Azetukalner for Patients with Epilepsy, Including Focal-onset and Primary Generalized Tonic-Clonic Seizures

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Xenon Pharmaceuticals Inc.

B-cell lymphoma+1

Recruiting

Long-term Study of Ibrutinib for Patients with B-cell Non-Hodgkin's Lymphoma and Chronic Graft Versus Host Disease

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Guimaraes

What the registry says about research in the country

01 Cardiovascular Research

Innovative studies focusing on TTR amyloidosis cardiomyopathy and treatments for hypertrophic cardiomyopathy. Research includes evaluations of new therapies for stroke prevention in patients with atrial fibrillation.

  • Heart Disease Management
  • Stroke Prevention
  • Cardiovascular Risk Reduction

Multiple trials examining breakthrough treatments for various forms of heart disease and their complications.

02 Respiratory Medicine

Clinical investigations into chronic rhinosinusitis treatments, both with and without nasal polyps. Studies evaluating new therapeutic approaches for respiratory conditions.

  • Nasal Polyp Treatment
  • Rhinosinusitis Management
  • Community-Acquired Pneumonia

Comprehensive research aimed at improving respiratory health outcomes and patient quality of life.

03 Neurological Disorders

Advanced research into multiple sclerosis and Alzheimer's disease related conditions. Studies focus on innovative treatments for both disease management and symptom control.

  • MS Treatment Development
  • Alzheimer's Psychosis
  • Epilepsy Management

Cutting-edge trials exploring new therapeutic options for various neurological conditions.

Back to PortugalAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.